BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 129,500 shares, a decline of 23.9% from the March 31st total of 170,200 shares. Based on an average daily trading volume, of 186,300 shares, the short-interest ratio is currently 0.7 days. Currently, 0.8% of the company's stock are short sold.
BioStem Technologies Stock Performance
Shares of OTCMKTS:BSEM traded up $0.07 during midday trading on Friday, hitting $14.03. 77,741 shares of the stock were exchanged, compared to its average volume of 67,225. The company has a market capitalization of $234.34 million, a PE ratio of 20.63 and a beta of 0.09. BioStem Technologies has a 52-week low of $6.77 and a 52-week high of $28.26. The business's fifty day simple moving average is $11.07 and its two-hundred day simple moving average is $13.92.
About BioStem Technologies
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Recommended Stories
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
